A nanoparticle formulation reduces the corneal toxicity of indomethacin eye drops and enhances its corneal permeability.

Abstract

Indomethacin (IMC) has been shown to reduce post-operative inflammation and to decrease intraocular irritation after cataract extraction and in cystoid macular edema; however, the clinical use of its most commonly used eye drops is limited due to topical side-effects that include burning sensation, irritation and epithelial keratitis. It is known that decreasing direct cell stimulation and reducing the amount applied via increasing bioavailability are useful for improving these issues. In this study, we designed ophthalmic formulations containing 0.5% IMC nanoparticles using zirconia beads and Bead Smash 12 (IMCnano eye drops; particle size 76 ± 59 nm, mean ± S.D.), and investigated the corneal toxicity of these IMCnano eye drops. IMCnano eye drops are tolerated better by a human cornea epithelial cell line (HCE-T) than commercially available NDSAIDs preparations (IMC, pranoprofen, diclofenac, bromfenac and nepafenac eye drops), and corneal wound healing in rat eyes with debrided corneal epithelium instilled with IMCnano eye drops is significantly better than that of eyes instilled with commercially available IMC eye drops. In addition, the accumulation of IMC in HCE-T cells treated with the IMCnano eye drops for 30 min was 19.9% that of the accumulation from commercially available IMC eye drops. On the other hand, the corneal penetration of IMC from IMCnano eye drops was significantly greater than in the case of the commercially available IMC eye drops in both in vivo and in vitro studies using rabbit corneas. Taken together, we hypothesize that a nanoparticle formulation reduces the corneal toxicity of IMC eye drops, probably because the accumulation of IMC from IMCnano eye drops in the eye is lower than that from commercially available IMC eye drops. In addition, the nanoparticle formulation may allow a decrease in the amount of IMC used due to the increase in bioavailability, resulting in reduced drug toxicity. These findings provide significant information that can be used to design further studies aimed at developing less toxic eye drops.

• Authors: Noriaki Nagai, Yoshimasa Ito, Norio Okamoto, Yoshikazu Shimomura
• Journal: Toxicology (Toxicology) Vol. 319 Pg. 53-62 (May 07 2014) ISSN: 1879-3185 [Electronic] Ireland
• PMID: 24598350 (Publication Type: Journal Article)
• Copyright: Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Benzalkonium Compounds
• Ophthalmic Solutions
• beta-Cyclodextrins
• 2-Hydroxypropyl-beta-cyclodextrin
• Mannitol
• Methylcellulose
• Zirconium
• zirconium oxide
• Indomethacin

Topics

• 2-Hydroxypropyl-beta-cyclodextrin
• Animals
• Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, chemistry)
• Bacterial Load
• Benzalkonium Compounds (administration & dosage, chemistry)
• Cell Line
• Cornea (drug effects, metabolism)
• Escherichia coli (drug effects, growth & development)
• Humans
• Indomethacin (administration & dosage, chemistry)
• Male
• Mannitol (chemistry)
• Methylcellulose (chemistry)
• Nanoparticles (administration & dosage, chemistry)
• Ophthalmic Solutions (administration & dosage, chemistry)
• Permeability
• Rats
• Rats, Wistar
• Wound Healing (drug effects)
• Zirconium (chemistry)
• beta-Cyclodextrins (chemistry)